Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway

• Published in: Pulmonary pharmacology & therapeutics 2015-06, Vol.32, p.29-36
• Main Authors: Kamio, Koichiro, Usuki, Jiro, Azuma, Arata, Matsuda, Kuniko, Ishii, Takeo, Inomata, Minoru, Hayashi, Hiroki, Kokuho, Nariaki, Fujita, Kazue, Saito, Yoshinobu, Miya, Toshimichi, Gemma, Akihiko
• Format: Article
• Language: English
• Subjects: A549; Animals; Cell Line, Tumor; Cell Proliferation - drug effects; Epithelial Cells - drug effects; Epithelial Cells - metabolism; Female; Humans; Idiopathic pulmonary fibrosis; Idiopathic Pulmonary Fibrosis - drug therapy; Idiopathic Pulmonary Fibrosis - physiopathology; Indoles - pharmacology; JNK Mitogen-Activated Protein Kinases - metabolism; Lung - cytology; Lung - drug effects; MAP Kinase Signaling System - drug effects; Medical Education; Mice; Mice, Inbred C57BL; Nintedanib; Pulmonary Surfactant-Associated Protein D - genetics; Pulmonary/Respiratory; RNA, Messenger - metabolism; Surfactant protein-D; Transcription Factor AP-1 - metabolism; Up-Regulation - drug effects
• ISSN: 1094-5539; 1522-9629
• DOI: 10.1016/j.pupt.2015.03.001

Abstract Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a high mortality rate. Signalling pathways activated by several tyrosine kinase receptors are known to be involved in lung fibrosis, and this knowledge has led to the development of the triple tyrosine kinase inhibitor nintedanib, an inhibitor of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), for the treatment of IPF. Pulmonary surfactant protein D (SP-D), an important biomarker of IPF, reportedly attenuates bleomycin-induced pulmonary fibrosis in mice. In this study, we investigated whether nintedanib modulates SP-D expression in human lung epithelial (A549) cells using quantitative real-time reverse transcriptase polymerase chain reaction and western blotting. To investigate the mechanisms underlying the effects of nintedanib, we evaluated the phosphorylation of c-Jun N-terminal kinase (JNK) and its downstream target c-Jun. The effect of the JNK inhibitor SP600125 on c-Jun phosphorylation was also tested. Activation of activator protein-1 (AP-1) was examined using an enzyme-linked immunosorbent assay-based test, and cell proliferation assays were performed to estimate the effect of nintedanib on cell proliferation. Furthermore, we treated mice with nintedanib to examine its in vivo effect on SP-D levels in lungs. These experiments showed that nintedanib up-regulated SP-D messenger RNA expression in a dose-dependent manner at concentrations up to 5 μM, with significant SP-D induction observed at concentrations of 3 μM and 5 μM, in comparison with that observed in vehicle controls. Nintedanib stimulated a rapid increase in phosphorylated JNK in A549 cells within 30 min of treatment and stimulated c-Jun phosphorylation, which was inhibited by the JNK inhibitor SP600125. Additionally, nintedanib was found to activate AP-1. A549 cell proliferation was not affected by nintedanib at any of the tested concentrations. Moreover, blocking FGFR, PDGFR, and VEGFR function did not affect nintedanib-induced SP-D expression, suggesting that nintedanib mediates its effects through a mechanism that is distinct from its known role as a tyrosine kinase inhibitor. Nintedanib is also reported to inhibit Src kinase although pre-treatment of cells with a Src kinase inhibitor had no effect on nintedanib-induced SP-D expression. Increased expression of SFTPD mRNA and SP-D protein in the lungs of nintedanib-